Reading Time: 6 minutes

Every year, new diagnostics and new treatments are introduced to the field of oncology. But knowing a treatment is not the same as prescribing it. Onclologists always need to choose a new treatment based on the patient’s profile, the strength of the evidence, and what the clinical situation demands.  

To examine how those decisions get made, Borderless Access conducted three research studies across different oncology areas: diffuse large B-cell lymphoma (DLBCL), head and neck cancer, and renal cell carcinoma (RCC). 

The findings offer a closer look at physician diagnostic practices, perceptions of an upcoming treatment, and the factors influencing brand awareness, usage, and prescribing behaviour. 

1. DLBCL Diagnosis: Understanding the Diagnostic Practices of Specialists 

Accurate diagnosis plays an important role in determining the course of cancer care. Understanding the diagnostic methods physicians rely on can provide pharmaceutical companies with a clearer picture of existing clinical practices and potential gaps in the diagnostic landscape. 

A Borderless Access study involving 100 hematologists and hemato-oncologists across the EU5 markets and the USA examined how specialists approach the diagnosis of diffuse large B-cell lymphoma (DLBCL). 

Conducted through a 10-minute online survey, the research explored the diagnostic methods physicians commonly use, including imaging, tissue or lymph node biopsies, and cell-of-origin (COO) classification. 

What diagnostic methods do physicians commonly use? 

The study examined the diagnostic methods specialists rely on when managing DLBCL patients. 

Imaging tests and tissue or lymph node biopsies emerged as the commonly reported diagnostic methods. The research also examined the use of complete blood counts, bone marrow biopsies, and lumbar punctures. 

These findings provide a view of the different diagnostic approaches reported by specialists and the role of various methods in current DLBCL diagnostic practices. 

How familiar are physicians with COO classification? 

Cell-of-origin classification is an important aspect of understanding DLBCL. The research examined physicians’ familiarity with this approach, including the use of immunohistochemistry (IHC) and gene expression testing. 

Among the surveyed physicians, 45% reported that COO classification was done through IHC, while 35% identified gene expression as the method used. Another 20% were unsure how COO classification was determined. 

The study also examined when these tests were conducted across different stages of the patient’s treatment journey, including initial diagnosis, during first-line treatment before switching to second-line treatment, and during second-line treatment before switching to third-line or later treatment. 

What does this reveal? 

The findings highlight the importance of understanding not only which diagnostic methods physicians use but also their familiarity with different classification approaches and when these are incorporated into clinical practice. 

For pharmaceutical companies, these insights provide a clearer understanding of the existing diagnostic landscape and can help inform broader business strategy and operations. 

2. Head and Neck Cancer Care: What Influences Physicians’ Willingness to Prescribe an Upcoming Treatment? 

Developing an oncology treatment involves understanding not only its potential clinical value but also how physicians perceive it and what could influence its eventual adoption. Physicians may respond positively to a treatment’s perceived efficacy and safety, but their willingness to prescribe it can also depend on practical considerations and potential barriers to adoption. 

To understand these factors, Borderless Access conducted research among 50 radiation oncologists across the USA, Germany, France, and Italy. The 30-minute online survey examined physician perceptions of an upcoming head and neck cancer treatment, including its perceived efficacy and safety, prescribing likelihood, adoption challenges, and potential barriers to its use. 

How likely are physicians to prescribe the upcoming treatment? 

The study findings indicated positive stated prescribing intent among the surveyed radiation oncologists. 

  • 50% said they would definitely prescribe the treatment once available. 
  • 30% said they would probably prescribe it once available. 

Together, these responses indicate that 80% of the surveyed physicians expressed positive stated prescribing intent. 

However, interest in a treatment that is still under development does not necessarily translate into future prescribing behaviour. Understanding the considerations that influence physicians’ willingness to prescribe it is equally important. 

What could influence treatment adoption? 

The study examined several practical and operational challenges associated with the potential adoption of the upcoming treatment. 

These included: 

  • Whether physicians’ practices were adequately equipped. 
  • Time constraints associated with treatment administration. 
  • Logistical challenges. 
  • Availability of staff. 
  • Infrastructure limitations. 

These considerations highlight why evaluating physician interest alone may not provide a complete picture of potential treatment adoption. 

The research also explored specific barriers that could influence physicians’ willingness to prescribe the treatment. 

These included concerns around treatment efficacy, limitations related to the indicated patient population, and practical considerations associated with administration. 

The study specifically examined factors such as: 

  • Duration of intravenous infusion. 
  • Time constraints between intravenous infusion and the start of intramuscular injection. 
  • The need for product administration before each intramuscular injection. 
  • Concerns about treatment efficacy. 
  • Limitations related to the patient population indicated for treatment. 

Together, these findings bring attention to the clinical and practical considerations that may influence a physician’s willingness to prescribe an upcoming treatment. 

What does this reveal? 

Understanding both positive perceptions and potential adoption barriers provides a more balanced view of a treatment’s market potential. The findings helped the client assess opportunities for the treatment under development, identify gaps, and support strategic planning and resource allocation around patient care and treatment outcomes. 

3. Renal Cell Carcinoma: What Drives Brand Prescription Among Oncologists? 

While understanding perceptions of an upcoming treatment is important before launch, pharmaceutical companies also need to understand how existing brands are viewed and used in clinical practice. In renal cell carcinoma (RCC), awareness of a treatment does not necessarily indicate its position in physicians’ prescribing decisions. Understanding what drives brand selection requires examining awareness, usage, perceptions, and treatment requirements together. 

Borderless Access conducted a study involving 500 medical oncologists and hematologists across the USA through a 60-minute online survey. 

The research examined physician perceptions of existing RCC treatment brands, the factors influencing prescription decisions, and treatment needs across neoadjuvant and metastatic settings. 

Prescription Drivers: Understanding What Influences Oncologist Choices 

The study compiled the factors influencing brand prescription, providing a clearer understanding of the attributes and considerations shaping oncologist choices. Rather than focusing only on which brands physicians recognise, the research examined the factors contributing to their treatment selections. 

Understanding these drivers helps pharmaceutical companies move beyond brand familiarity to examine what influences treatment choices. 

Brand Awareness and Usage: Two Different Measures 

The research assessed brand awareness alongside reported brand usage to understand the relationship between familiarity and prescribing behaviour. Separating these measures helps distinguish between physicians knowing a treatment and reporting its use in clinical practice. 

This distinction is important when evaluating brand performance, as awareness alone cannot establish a treatment’s place in prescribing behaviour. The study also examined brand awareness and willingness to prescribe across first-line and second-line RCC treatment. It also considered current and future therapy needs in neoadjuvant and metastatic settings. 

Taking these factors into consideration provided a broader view of the treatment contexts in which oncologists evaluate available brands and consider different treatment options. 

Brand Commitment and Actual Prescription Behaviour 

Another important dimension of the research was the relationship between brand commitment and prescription behaviour. The study generated real-time prescription insights to examine this relationship, offering a more nuanced understanding of brand performance. For pharmaceutical companies, this distinction can help identify where brand perceptions and reported prescribing behaviour may differ. 

Translating Prescription Insights into Brand Communication 

The findings enabled the client’s marketing teams to customise brand messaging for oncologists around the key drivers of prescription. By connecting awareness, usage, perceptions, and prescribing behaviour, the research provided a stronger basis for brand communication and helped the client better understand opportunities across different treatment settings. 

4. What Do These Three Oncology Studies Reveal About Physician Decision-Making? 

Although the three studies focused on different oncology conditions and research objectives, they highlight a common consideration: understanding physician decisions requires looking beyond individual measures. 

Each study offers a different perspective on the factors shaping oncology care. 

Research area What the research uncovered 
DLBCL diagnostic practices Diagnostic methods, biopsy practices, COO classification familiarity, and timing 
Emerging head and neck cancer treatment Physician perceptions, stated prescribing intent, and potential adoption barriers 
RCC brand research Prescription drivers, brand awareness, usage, treatment-line considerations, and brand commitment 

Together, these findings demonstrate three important dimensions of healthcare research. 

Clinical practices provide context

Examining diagnostic methods and classification practices helps establish how specialists approach a particular indication. 

Treatment perceptions reveal potential interest

Understanding how physicians evaluate an upcoming treatment, alongside their stated prescribing intent, provides an indication of its potential market reception. 

Prescription drivers offer a deeper view of brand behaviour

Examining awareness alongside usage and the factors influencing prescription helps pharmaceutical companies understand how existing brands are positioned in clinical practice. 

Each factor answers a different business question. When examined together, they provide a broader understanding of the clinical and behavioural considerations shaping physician decisions. 

Turning Physician Insights into More Informed Healthcare Strategies 

The three studies highlight how oncology treatment decisions are shaped by multiple considerations, from diagnostic practices and treatment perceptions to adoption barriers and brand-related prescribing factors. 

For pharmaceutical companies, understanding these decisions requires looking beyond individual measures such as brand awareness or prescribing intent. It means examining how physicians evaluate treatment options, what influences their choices, and which clinical or practical considerations may affect their decisions across different indications and stages of care. 

Through its healthcare research, Borderless Access has examined different dimensions of oncology decision-making, including diagnostic practices in DLBCL, perceptions of an upcoming head and neck cancer treatment, and brand awareness and prescription drivers in RCC. 

These studies demonstrate how focused physician research can help pharmaceutical teams develop a clearer understanding of clinical practices, identify potential opportunities and barriers, and connect physician perspectives with broader business and marketing objectives. 

Ultimately, better-informed healthcare strategies begin with understanding the specialists, considerations, and clinical contexts that shape treatment decisions.